Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Apolo Website

Andrea B. Apolo, M.D.

Selected Publications

1)  Yavuz S, Apolo AB, Kummar S, Del Rivero J, Madan RA, Shawker T, Reynolds J, Celi FS.
Cabozantinib-induced thyroid dysfunction: a review of two ongoing trials for metastatic bladder cancer and sarcoma.
Thyroid. 24: 1223-31, 2014.
2)  Sternberg CN, Apolo AB.
Everything old is new again! Neoadjuvant chemotherapy in the treatment of muscle-invasive bladder cancer.
J. Clin. Oncol. 32: 1868-70, 2014.
3)  Apolo AB, Kim JW, Bochner BH, Steinberg SM, Bajorin DF, Kevin Kelly W, Agarwal PK, Koppie TM, Kaag MG, Quinn DI, Vogelzang NJ, Sridhar SS.
Examining the management of muscle-invasive bladder cancer by medical oncologists in the United States.
Urol. Oncol. 32: 637-44, 2014.
4)  Park JC, Citrin DE, Agarwal PK, Apolo AB.
Multimodal management of muscle-invasive bladder cancer.
Curr Probl Cancer. 38: 80-108, 2014.
5)  Cowan NG, Chen Y, Downs TM, Bochner BH, Apolo AB, Porter MP, La Rochelle JC, Amling CL, Koppie TM.
Neoadjuvant chemotherapy use in bladder cancer: a survey of current practice and opinions.
Adv Urol. 2014: [Epub ahead of print], 2014.
6)  Nakrani RN, Ghosh A, Richard Lee C, Agarwal PK, Apolo AB, Cowen EW.
New facial papules in a 66-year-old woman with bladder cancer.
J. Am. Acad. Dermatol. [Epub ahead of print], 2014.
7)  Agarwal N, Apolo AB, Tsao C, Lee KM, Godbold JH, Soto R, Poole A, Gimpel-Tetra K, Lowe N, Oh WK, Galsky MD.
Phase Ib/II Trial of Gemcitabine, Cisplatin, and Lenalidomide as First-Line Therapy in Patients With Metastatic Urothelial Carcinoma.
Oncologist. [Epub ahead of print], 2014.
8)  Pichard DC, Hensley JR, Williams E, Apolo AB, Klion AD, DiGiovanna JJ.
Rapid development of migratory, linear, and serpiginous lesions in association with immunosuppression.
J. Am. Acad. Dermatol. 70: 1130-4, 2014.
9)  Apolo AB, Hoffman V, Kaag MG, Latini DM, Lee CT, Rosenberg JE, Knowles M, Theodorescu D, Czerniak BA, Efstathiou JA, Albert ML, Sridhar SS, Margulis V, Matin SF, Galsky MD, Hansel D, Kamat AM, Flaig TW, Smith AB, Messing E, Zipursky Quale D, Lotan Y.
Summary of the 8th Annual Bladder Cancer Think Tank: Collaborating to move research forward.
Urol. Oncol. [Epub ahead of print], 2014.
10)  Ghosh M, Brancato SJ, Agarwal PK, Apolo AB.
Targeted therapies in urothelial carcinoma.
Curr Opin Oncol. 26: 305-20, 2014.
11)  Folio LR, Sandouk A, Huang J, Solomon JM, Apolo AB.
Consistency and efficiency of CT analysis of metastatic disease: semiautomated lesion management application within a PACS.
AJR Am J Roentgenol. 201: 618-25, 2013.
12)  Kohaar I, Porter-Gill P, Lenz P, Fu YP, Mumy A, Tang W, Apolo AB, Rothman N, Baris D, Schned AR, Ylaya K, Schwenn M, Johnson A, Jones M, Kida M, Silverman DT, Hewitt SM, Moore LE, Prokunina-Olsson L.
Genetic variant as a selection marker for anti-prostate stem cell antigen immunotherapy of bladder cancer.
J. Natl. Cancer Inst. 105: 69-73, 2013.
13)  Balar AV, Apolo AB, Ostrovnaya I, Mironov S, Iasonos A, Trout A, Regazzi AM, Garcia-Grossman IR, Gallagher DJ, Milowsky MI, Bajorin DF.
Phase II study of gemcitabine, carboplatin, and bevacizumab in patients with advanced unresectable or metastatic urothelial cancer.
J. Clin. Oncol. 31: 724-30, 2013.
14)  Apolo AB, Ostrovnaya I, Halabi S, Iasonos A, Philips GK, Rosenberg JE, Riches J, Small EJ, Milowsky MI, Bajorin DF.
Prognostic model for predicting survival of patients with metastatic urothelial cancer treated with Cisplatin-based chemotherapy.
J. Natl. Cancer Inst. 105: 499-503, 2013.
15)  Apolo AB, Kwiatkowski DJ.
Targeting molecular aberrations in urothelial carcinoma.
Am Soc Clin Oncol Educ Book. 2013: 195-9, 2013.
16)  Svatek RS, Rosenberg JE, Galsky MD, Lee CT, Latini DM, Bochner BH, Weizer AZ, Apolo AB, Sridhar SS, Kamat AM, Hansel D, Flaig TW, Smith ND, Lotan Y.
Summary of the 6th annual bladder cancer think tank: New directions in urologic research.
Urol. Oncol. [Epub ahead of print], 2012.
17)  Kurdziel KA, Shih JH, Apolo AB, Lindenberg L, Mena E, McKinney YY, Adler SS, Turkbey B, Dahut W, Gulley JL, Madan RA, Landgren O, Choyke PL.
The kinetics and reproducibility of 18F-sodium fluoride for oncology using current PET camera technology.
J. Nucl. Med. 53: 1175-84, 2012.
18)  Alarcon SV, Mollapour M, Lee MJ, Tsutsumi S, Lee S, Kim YS, Prince T, Apolo AB, Giaccone G, Xu W, Neckers LM, Trepel JB.
Tumor-intrinsic and tumor-extrinsic factors impacting hsp90- targeted therapy.
Curr. Mol. Med. 12: 1125-41, 2012.
19)  Apolo AB, Grossman HB, Bajorin D, Steinberg G, Kamat AM.
Practical use of perioperative chemotherapy for muscle-invasive bladder cancer: summary of session at the Society of Urologic Oncology annual meeting.
Urol. Oncol. 30: 772-80, 2011.
20)  Apolo AB, Riches J, Schoder H, Akin O, Trout A, Milowsky MI, Bajorin DF.
Clinical Value of Fluorine-18 2-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography/Computed Tomography in Bladder Cancer.
J Clin Oncol. 28: 3973-8, 2010.
21)  Apolo AB, Milowsky M, Bajorin DF.
Clinical states model for biomarkers in bladder cancer.
Future Oncol. 5: 977-92, 2009.
22)  Apolo AB, Pandit-Taskar N, Morris MJ.
Novel tracers and their development for the imaging of metastatic prostate cancer.
J. Nucl. Med. 49: 2031-41, 2008.
Click Here to View Collapsed Bibliography.

This page was last updated on 8/21/2014.